Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models

Research output: Chapter in Book/Report/Conference proceedingChapter

7 Citations (Scopus)

Abstract

An important aspect of tumor growth is the continued 'physiologic' functioning of intratumoral blood vessels, effectively delivering oxygen and nutrients. Vascular disrupting agents (VDA) target this component of tumor vasculature, bringing about a rapid and catastrophic shutdown and consequent tumor necrosis. Using three animal tumor models and different VDAs we detail the morphologic and morphometric evolution of VDA induced tumor injury. While there are quantitative and chronologic differences, qualitative morphologic alterations are strikingly similar between the tumor models and VDAs investigated. Functional vascular shutdown is identified by fluorescent microscopy within the first hour following parenteral delivery of the drug. As the tumor undergoes frank necrosis, intratumoral vessels are irreversibly damaged. The pattern of injury is typical of vascular compromise, with necrosis interspersed with areas of red cell extravasation. In each of the models, surviving tumor persists as a peripheral, viable rim of neoplastic elements that has a clear and significant potential for regrowth. The morphologic changes manifest by use of these agents, provide important clues to understanding the mechanisms that operate in the induction of this antitumor activity.

Original languageEnglish (US)
Title of host publicationVascular-Targeted Therapies in Oncology
PublisherJohn Wiley & Sons, Ltd
Pages81-94
Number of pages14
ISBN (Print)9780470012949
DOIs
StatePublished - May 31 2006

Fingerprint

Blood Vessels
Tumors
Neoplasms
Necrosis
Wounds and Injuries
Blood vessels
Nutrients
Microscopy
Microscopic examination
Animals
Animal Models
Cells
Oxygen
Food
Growth
Pharmaceutical Preparations

Keywords

  • Combretastatin and ZD6126
  • Effects of treatment
  • Human Kaposi's sarcoma (KSY-1) and renal cell carcinoma Caki-1 xenograft
  • Intratumoral vascular damage
  • Targeting tumor vasculature
  • Tumor supportive blood vessel attack
  • Vascular disrupting agents (VDA)
  • Vascular-disrupting agents in preclinical models

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models. / Rojiani, Mumtaz V; Rojiani, Amyn Mohammed.

Vascular-Targeted Therapies in Oncology. John Wiley & Sons, Ltd, 2006. p. 81-94.

Research output: Chapter in Book/Report/Conference proceedingChapter

Rojiani, Mumtaz V ; Rojiani, Amyn Mohammed. / Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models. Vascular-Targeted Therapies in Oncology. John Wiley & Sons, Ltd, 2006. pp. 81-94
@inbook{85ad9fa728784d0ab4d334d82feab58d,
title = "Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models",
abstract = "An important aspect of tumor growth is the continued 'physiologic' functioning of intratumoral blood vessels, effectively delivering oxygen and nutrients. Vascular disrupting agents (VDA) target this component of tumor vasculature, bringing about a rapid and catastrophic shutdown and consequent tumor necrosis. Using three animal tumor models and different VDAs we detail the morphologic and morphometric evolution of VDA induced tumor injury. While there are quantitative and chronologic differences, qualitative morphologic alterations are strikingly similar between the tumor models and VDAs investigated. Functional vascular shutdown is identified by fluorescent microscopy within the first hour following parenteral delivery of the drug. As the tumor undergoes frank necrosis, intratumoral vessels are irreversibly damaged. The pattern of injury is typical of vascular compromise, with necrosis interspersed with areas of red cell extravasation. In each of the models, surviving tumor persists as a peripheral, viable rim of neoplastic elements that has a clear and significant potential for regrowth. The morphologic changes manifest by use of these agents, provide important clues to understanding the mechanisms that operate in the induction of this antitumor activity.",
keywords = "Combretastatin and ZD6126, Effects of treatment, Human Kaposi's sarcoma (KSY-1) and renal cell carcinoma Caki-1 xenograft, Intratumoral vascular damage, Targeting tumor vasculature, Tumor supportive blood vessel attack, Vascular disrupting agents (VDA), Vascular-disrupting agents in preclinical models",
author = "Rojiani, {Mumtaz V} and Rojiani, {Amyn Mohammed}",
year = "2006",
month = "5",
day = "31",
doi = "10.1002/0470035439.ch5",
language = "English (US)",
isbn = "9780470012949",
pages = "81--94",
booktitle = "Vascular-Targeted Therapies in Oncology",
publisher = "John Wiley & Sons, Ltd",

}

TY - CHAP

T1 - Morphologic Manifestations of Vascular-disrupting Agents in Preclinical Models

AU - Rojiani, Mumtaz V

AU - Rojiani, Amyn Mohammed

PY - 2006/5/31

Y1 - 2006/5/31

N2 - An important aspect of tumor growth is the continued 'physiologic' functioning of intratumoral blood vessels, effectively delivering oxygen and nutrients. Vascular disrupting agents (VDA) target this component of tumor vasculature, bringing about a rapid and catastrophic shutdown and consequent tumor necrosis. Using three animal tumor models and different VDAs we detail the morphologic and morphometric evolution of VDA induced tumor injury. While there are quantitative and chronologic differences, qualitative morphologic alterations are strikingly similar between the tumor models and VDAs investigated. Functional vascular shutdown is identified by fluorescent microscopy within the first hour following parenteral delivery of the drug. As the tumor undergoes frank necrosis, intratumoral vessels are irreversibly damaged. The pattern of injury is typical of vascular compromise, with necrosis interspersed with areas of red cell extravasation. In each of the models, surviving tumor persists as a peripheral, viable rim of neoplastic elements that has a clear and significant potential for regrowth. The morphologic changes manifest by use of these agents, provide important clues to understanding the mechanisms that operate in the induction of this antitumor activity.

AB - An important aspect of tumor growth is the continued 'physiologic' functioning of intratumoral blood vessels, effectively delivering oxygen and nutrients. Vascular disrupting agents (VDA) target this component of tumor vasculature, bringing about a rapid and catastrophic shutdown and consequent tumor necrosis. Using three animal tumor models and different VDAs we detail the morphologic and morphometric evolution of VDA induced tumor injury. While there are quantitative and chronologic differences, qualitative morphologic alterations are strikingly similar between the tumor models and VDAs investigated. Functional vascular shutdown is identified by fluorescent microscopy within the first hour following parenteral delivery of the drug. As the tumor undergoes frank necrosis, intratumoral vessels are irreversibly damaged. The pattern of injury is typical of vascular compromise, with necrosis interspersed with areas of red cell extravasation. In each of the models, surviving tumor persists as a peripheral, viable rim of neoplastic elements that has a clear and significant potential for regrowth. The morphologic changes manifest by use of these agents, provide important clues to understanding the mechanisms that operate in the induction of this antitumor activity.

KW - Combretastatin and ZD6126

KW - Effects of treatment

KW - Human Kaposi's sarcoma (KSY-1) and renal cell carcinoma Caki-1 xenograft

KW - Intratumoral vascular damage

KW - Targeting tumor vasculature

KW - Tumor supportive blood vessel attack

KW - Vascular disrupting agents (VDA)

KW - Vascular-disrupting agents in preclinical models

UR - http://www.scopus.com/inward/record.url?scp=33750504410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750504410&partnerID=8YFLogxK

U2 - 10.1002/0470035439.ch5

DO - 10.1002/0470035439.ch5

M3 - Chapter

AN - SCOPUS:33750504410

SN - 9780470012949

SP - 81

EP - 94

BT - Vascular-Targeted Therapies in Oncology

PB - John Wiley & Sons, Ltd

ER -